Liverpool Ocular Oncology<br />Research Group
 
  • HOME
  • NEWS
  • Research Team
  • Disease Focus and Research
    • Uveal Melanoma
    • Conjunctival melanoma
    • Ocular Adnexal Lymphoma
  • Molecular Pathology
  • Ocular Oncology Biobank (OOB)
  • Paper Publications
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
    • 2011
    • 2010
    • 2009
    • 2008
    • 2007
    • 2006
    • 2005
    • 2004
  • Book Chapters
  • Informative Videos
  • Alumni
    • Previous Staff
    • Past PhD Students
    • Past MD Students
    • Past MRes Students
    • Past BSc/MSc Students
    • Nuffield Students
  • Visitors
    • Visiting researchers and clinicians
    • Visiting Students
  • Support Us/Donations
  • Fundraising Events
  • Training and Opportunities
  • Contact us
  • Links
Picture
Picture

Proteomic discovery of serum biomarkers in metastatic uveal melanoma

Dr Martina Angi
Dr Helen Kalirai
Prof. Sarah Coupland
Prof. Bertil Damato

Summary

In patients with uveal melanoma clinically evident metastatic disease is almost invariably refractive to current treatment strategies. Earlier detection of metastatic disease may potentially increase the effectiveness of such therapies. Moreover, an effective strategy would be to suppress micro-metastases before they progress, adopting systemic therapy in the adjuvant setting for high risk patients. As metastatic spread occurs haematogeneously, a sensitive and specific serological marker that can be measured on routine blood samples would allow earlier detection of metastatic disease and aid monitoring of systemic adjuvant therapy in high risk uveal melanoma patients. This study aims to identify such a biomarker(s) of metastatic disease by focusing on both the secretome of the primary tumour and circulating tumour cells.

Funded by:

Picture
Powered by Create your own unique website with customizable templates.